Predictors of bone density in ambulatory patients on antiepileptic drugs

Bone

Volumn 43, Issue 1, 2008, Pages 149-155

  El Hajj Fuleihan, Ghada ^a   Dib, Lea ^a   Yamout, Bassem ^a   Sawaya, Raja ^a   Mikati, Mohamad A ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Antiepileptic drugs; Bone density; Enzyme inducers; Polypharmacy; Therapy duration; Vitamin D

Indexed keywords

CARBAMAZEPINE; CLONAZEPAM; ETHOSUXIMIDE; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; VIGABATRIN;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE; ARTICLE; BONE DENSITY; CALCIUM INTAKE; CONTROLLED STUDY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME INDUCTION; EPILEPSY; FEMALE; HIP; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIVARIATE ANALYSIS; PATIENT INFORMATION; POLYPHARMACY; POPULATION RISK; PREDICTION; RISK ASSESSMENT; SPINE; TREATMENT DURATION; VITAMIN D DEFICIENCY;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; ADULT; ANTICONVULSANTS; BONE DENSITY; CASE-CONTROL STUDIES; CHILD; EPILEPSY; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; QUESTIONNAIRES; VITAMIN D DEFICIENCY;

EID: 44949145108     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2008.03.002     Document Type: Article

References (30)

1. Epilepsy Foundation. accessed on April 11, 2008 at http://www.epilepsyfoundation.org/about/statistics.cfm.
2. Drezner M.K. Treatment of anticonvulsant drug-induced bone disease. Epilepsy Behav 5 Suppl 2 (2004) S41-S47
3. Fitzpatrick L. Pathophysiology of bone loss in patients receiving anticonvulsant therapy. Epilepsy Behav 5 (2004) S3-S15
4. Ensrud K.E., Blackwell T., Mangione C.M., Bowman P.J., Bauer D.C., Schwartz A., et al., Study of Osteoporotic Fractures Research Group. Central nervous system active medications and risk for fractures in older women. Arch Intern Med 163 (2003) 949-957
5. Farhat G., Yamout B., Mikati M.A., Demirjian S., Sawaya R., and El-Hajj Fuleihan G. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 58 (2002) 1348-1353
6. Pack A.M., Olarte L.S., Morrell M.J., Flaster E., Resor S.R., and Shane E. Bone mineral density in an outpatient population receiving enzyme-inducing antiepileptic drugs. Epilepsy Behav 4 (2003) 169-174
7. Sheth R.D., Wesolowski C.A., Jacob J.C., Penney S., Hobbs G.R., Riggs J.E., et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr 127 (1995) 256-262
8. Akin R., Okutan V., Sarici U., Altunbas A., and Gokcay E. Evaluation of bone mineral density in children receiving antiepileptic drugs. Pediatr Neurol 19 (1998) 129-131
9. Kulak C.A., Borba V.Z., Bilezikian J.P., Silvado C.E., Paola L., and Boguszewski C.L. Bone mineral density and serum levels of 25 OH vitamin D in chronic users of antiepileptic drugs. Arq Neuropsiquiatr 62 (2004) 940-948
10. Valimaki M.J., Tiihonen M., Laitinen K., Tahtela R., Karkkainen M., Lamberg-Allardt C., et al. Bone mineral density measured by dual-energy X-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J Bone Miner Res 9 (1994) 631-637
11. Sato Y., Kondo I., Ishida S., Motooka H., Takayama K., Tomita Y., et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 57 (2001) 445-449
12. Mikati M.A., Dib L., Yamout B., Sawaya R., Rahi A.C., and Fuleihan G.e.l.H. Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone. Neurology 67 (2006) 2005-2014
13. El-Hajj Fuleihan G., Baddoura R., Awada H., Salam N., Salamoun M., and Rizk P. Low peak bone mineral density in healthy Lebanese subjects. Bone 31 (2002) 520-528
14. El-Hajj Fuleihan G., Nabulsi M., Tamim H., Maalouf J., Salamoun M., Khalife H., et al. Effect of vitamin D replacement on musculoskeletal parameters in healthy school children: a randomized controlled trial. J Clin Endocrinol Metab 91 (2006) 405-412
15. Salamoun M.M., Kizirian A.S., Tannous R.I., Nabulsi M.M., Choucair M.K., Deeb M.E., et al. Low calcium and vitamin D intake in healthy children and adolescents and their correlates. Eur J Clin Nutr 59 (2005) 177-184
16. NIH consensus conference. Optimal calcium intake. NIH consensus development panel on optimal calcium intake. JAMA 272 (1994) 1942-1948
17. McKenna M.J., and Freaney R. Secondary hyperparathyroidism in the elderly: means to defining hypovitaminosis D. Osteoporos Int 8 (1998) S3-S6
18. Dawson-Hughes B., Heaney R.P., Holick M.F., Lips P., Meunier P.J., and Vieth R. Estimates of optimal vitamin D status. Osteoporos Int 16 (2005) 713-716
19. Genant H.K., Grampp S., Gluer C.C., Faulkner K.G., Jergas M., Engelke K., et al. Universal standardization for dual X-ray absorptiometry: patient and phantom cross-calibration results. J Bone Miner Res 10 (1994) 1503-1514
20. Mosekilde L., Christensen S.C., Lund B., Sorensen O.H., and Melsen F. The interrelationships between serum 25-hydroxycholcalciferol, serum parathyroid hormone and bone changes in anticonvulsant osteomalacia. Acta Endocrinol 84 (1977) 559-565
21. Verrotti A., Greco R., Latini G., Morgese G., and Chiarelli F. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 43 (2002) 1488-1492
22. Bischoff-Ferrari H.A., Dietrich T., Orav E.J., and Dawson-Hughes B. Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med 116 (2004) 634-639
23. Corradino R.A. Diphenylhydantoin: direct inhibition of the vitamin D3-mediated calcium absorptive mechanism in organ-cultured duodenum. Biochem Pharmacol 25 (1976) 863-864
24. Feldkamp J., Becker A., Witte O.W., Scharff D., and Scherbaum W.A. Long-term anticonvulsant therapy leads to low bone mineral density - evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp Clin Endocrinol Diabetes 108 (2000) 37-43
25. Isojarvi J.I., Pakarinen A.J., Ylipalosaari P.J., and Myllyla V.V. Serum hormones in male epileptic patients receiving anticonvulsant medication. Arch Neurol 47 (1990) 670-676
26. Ensrud K.E., Walczak T.S., Blackwell T., Ensrud E.R., Bowman P.J., and Stone K.L. Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology 62 (2004) 2051-2057
27. Petty S.J., Paton L.M., O'Brien T.J., Makovey J., Erbas B., Sambrook P., et al. Effect of antiepileptic medication on bone mineral measures. Neurology 65 (2005) 1358-1365
28. Marshall D., Johnell O., and Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312 (1996) 1254-1259
29. Guo C.Y., Ronen G.M., and Atkinson S.A. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 42 (2001) 1141-1147
30. Kafali G., Erselcan T., and Tanzer F. Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12. Clin Pediatr 38 (1999) 93-98